aap signs exclusive license agreement for an IP-protected product of its biomaterial portfolio

Berlin, (PresseBox) - aap Biomaterials GmbH, a subsidiary of aap Implantate AG, a medical technology company listed in the Frankfurt Stock Exchange's Prime Standard segment, today signed an exclusive license agreement with a world-leading medical technology company. aap has granted an exclusive license to an IP-protected product of its biomaterial portfolio and remains at the same time the product's manufacturer. The exclusive license relates to all product indications, excluding Dental, oral care and food additives and is valid worldwide except in the United States.

With the signing, aap will receive a one-time license fee of approx. EUR 2.1 million.

Press releases you might also be interested in

Weitere Informationen zum Thema "Medizintechnik":

Brain Control – eine neue Form der Künstlichen Intelligenz

In­for­ma­ti­ker der Uni Tü­bin­gen ha­ben ein Com­pu­ter­pro­gramm ent­wi­ckelt, das ei­ne neue Form der Künst­li­chen In­tel­li­genz dar­s­tellt. Bei Brain Con­trol kom­mu­ni­ziert man mit vir­tu­el­len Fi­gu­ren in men­sch­li­cher Spra­che, er­klärt ih­nen Din­ge, gibt An­wei­sun­gen oder mo­ti­viert sie, Si­tua­tio­nen selbst zu er­kun­den.

Weiterlesen

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.